Article Text

PDF
AB0223 SLC19A1, SLCO1B1 and ABCG2 Polymorphisms Are Associated with Methotrexate-Related Gastrointestinal Toxicity in Portuguese Rheumatoid Arthritis Patients
  1. A. Lima1,2,3,
  2. A.R. Azevedo1,
  3. H. Sousa1,
  4. M. Bernardes4,
  5. R. Medeiros1,
  6. V. Seabra3
  1. 1Molecular Oncology Group CI, Portuguese Institute of Oncology of Porto (IPO-Porto)
  2. 2Abel Salazar Institute for the Biomedical Sciences (ICBAS), University of Porto, Porto
  3. 3Department of Pharmaceutical Sciences, Higher Institute of Health Sciences (ISCS-N), IINFACTS/CESPU, Institute of Research and Advanced Training in Health Sciences and Technologies, Gandra PRD
  4. 4Rheumatology Department of São João Hospital Center, São João Hospital Cente, Porto, Portugal

Abstract

Background Methotrexate (MTX) is used for rheumatoid arthritis (RA) treatment with a wide variety of clinical responses1. Therefore, studies have been conducted to help elucidate the potential role of genetic polymorphisms in MTX influx and efflux transporters (solute carriers – SLC and ATP-binding cassette – ABC, respectively) as well as in the development of MTX-related gastrointestinal toxicity (MTX-GastroTox)2.

Objectives We aimed to evaluate the influence of several single nucleotide polymorphisms (SNP) in genes that codify to MTX transporters with the occurrence of MTX-GastroTox in Portuguese RA patients.

Methods A total of 233 RA patients were included in the study and genotyped by Sequenom MassARRAY® for 20 SNPs (SLC16A7, SLC19A1, SLC22A6, SLC22A11, SLC46A1, SLCO1B1, ABCB1, ABCC1, ABCC2 and ABCG2). Binary logistic regression analyses were performed and adjusted to possible confounder variables (related to patient, disease and treatment). Haplotype analysis was used to test SNPs that revealed to be statistically significant and a risk index for MTX-GastroTox was created.

Results In this population, SLC19A1 rs7499 G carriers (p=0.013, OR=5.46), SLC19A1 rs1051266 G carriers (p=0.039, OR=2.94), SLCO1B1 rs4149056 T carriers (p=0.039, OR=3.13) and ABCG2 rs13120400 C carriers (p=0.042, OR=2.26) were associated with increased risk for MTX-GastroTox. SLC19A1 rs7499 and rs1051266 revealed to be in linkage disequilibrium (p<0.001, D'=0.81) with the AA haplotype being associated with MTX-GastroTox protection (p=0.024, OR=0.45). In addition, the risk index revealed that patients with 3 or 4 risk variants (SLC19A1 rs7499 GG, SLC19A1 rs1051266 GG, SLCO1B1 rs4149056 TT and ABCG2 rs13120400 CC) had a 13-fold increased risk for MTX-GastroTox (p=0.006, OR=13.4).

Conclusions SLC19A1, SLCO1B1 and ABCG2 genotyping may be a useful tool for assist clinicians to identify patients at higher risk for developing gastrointestinal toxicity related with MTX treatment.

References

  1. Tian H, Cronstein BN. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bulletin of the NYU hospital for joint diseases. [Review]. 2007;65(3):168-73.

  2. Lima A, Bernardes M, Sousa H, Azevedo R, Costa L, Ventura F, et al. SLC19A1 80G allele as a biomarker of methotrexate-related gastrointestinal toxicity in Portuguese rheumatoid arthritis patients. Pharmacogenomics. 2013:1-14

Acknowledgements The authors wish to acknowledge to Fundação para a Ciência e Tecnologia (FCT) for the Doctoral Grant (SFRH/BD/64441/2009) for Aurea Lima and also to the nursing service of Rheumatology Day Hospital of São João Hospital Center and the clinicians from the Rheumatology Department of São João Hospital Center.

Disclosure of Interest None declared

DOI 10.1136/annrheumdis-2014-eular.4711

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.